Evidence map›Paper›PMID 40938943›Full record

ArticleAmerican journal of physiology. Cell physiology2025

Short-term daily deflazacort decreases membrane permeability and increases maximum force in

Kristen D Turner, Ying Qian, Dennis R Claflin, Breanne L Newell-Stamper, Angela K Peter, Daniel E Michele, Alan J Russell, Susan V Brooks

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Cell physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kristen D TurnerDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States.ORCID 0000-0003-4418-5281
Ying QianEdgewise Therapeutics, BioFrontiers Institute, University of Colorado, Boulder, Colorado, United States.ORCID 0000-0001-8595-2219
Dennis R ClaflinDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States.ORCID 0000-0001-8044-0142
Breanne L Newell-StamperEdgewise Therapeutics, BioFrontiers Institute, University of Colorado, Boulder, Colorado, United States.
Angela K PeterEdgewise Therapeutics, BioFrontiers Institute, University of Colorado, Boulder, Colorado, United States.ORCID 0000-0003-4496-2511
Daniel E MicheleDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States.ORCID 0000-0003-4393-4551
Alan J RussellEdgewise Therapeutics, BioFrontiers Institute, University of Colorado, Boulder, Colorado, United States.ORCID 0000-0001-7545-5008
Susan V BrooksDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States.ORCID 0000-0003-1954-967X

Funding

Costamere Defects in Muscular DystrophiesR01AR049899 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI ERVASTI, JAMES M · 2005 to 2025
$8.2M
Michigan IRACDA: Training Future Professors of Engineering and PhysiologyK12GM111725 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROOKS, SUSAN V, SEPT, DAVID · 2016 to 2025
$7.9M
Edgewise TherapeuticsHHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) AR049899HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM111725NIAMS NIH HHS R01 AR049899NIGMS NIH HHS K12 GM111725
6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by the absence of dystrophin, which leads to mechanical instability of the muscle fiber membrane and a predisposition for cell membrane permeability and contraction-induced muscle injury. Deflazacort is an FDA-approved corticosteroid for treating DMD, and treatment of dystrophic mice with deflazacort reduces inflammation and improves muscle regeneration. Whether deflazacort protects from contraction-induced injury in

Indexed as

Cell Membrane PermeabilityMuscle, SkeletalMuscle StrengthMuscular Dystrophy, DuchennePregnenedionesAnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLMice, Inbred mdxMuscle ContractionMuscle Fibers, SkeletaldeflazacortPregnenedionesdeflazacortglucocorticoidsmuscular dystrophyskeletal muscle

Identifiers

PMID40938943
PMCPMC12687555

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.